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Background: Gallbladder cancer (GBC) is a relatively uncommon carcinoma among gastrointestinal cancers and
usually has a rather poor prognosis. The most common subtype of GBC is adenocarcinoma (AC), which accounts
for about 90% of GBC. Squamous carcinoma/adenosquamous carcinoma (SC/ASC) are comparatively rare
histopathological subtypes of GBC. The clinicopathological features and biological behaviors of SC/ASC have not
been well-characterized. No molecular biomarkers are currently available for predicting the progression, metastasis,
and prognosis of the SC/ASC subtype of GBC.
Methods: We examined the expression levels of CCT2 and PDIA3 by immunohistochemistry (IHC) staining in
human GBC tissue samples collected from 46 patients with SC/ASC and evaluated the clinicopathological
significance of both CCT2 and PDIA3 expression in the SC/ASC subtypes of GBC by Kaplan-Meier analysis and
multivariate Cox regression analysis. For comparison, we included specimens from 80 AC patients in our study to
investigate the specificity of CCT2 and PDIA3 expression in GBC subtypes.
Results: We found that the positive expression of CCT2 and PDIA3 was significantly associated with
clinicopathological features of both SC/ASC and AC specimens, including high TNM stage and lymph node
metastasis. Univariate analysis revealed that the two-year survival rate was significantly lower for patients with
positive expression of CCT2 and PDIA3 than for those with negative expression. Multivariate analysis also indicated
that the positive expression of CCT2 and PDIA3 was negatively correlated with poor postoperative patient survival
and positively correlated with high mortality.
Conclusions: Our study suggests that positive expression of CCT2 or PDIA3 is associated with tumor progression
and the clinical behavior of gallbladder carcinoma. Therefore, CCT2 and PDIA3 could be potentially important
diagnostic and prognostic biomarkers for both SC/ASC and AC subtypes of GBC.
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Gallbladder cancer (GBC) is a relatively uncommon
gastrointestinal carcinoma, but its incidence is increasing
worldwide and its prognosis is rather poor [1]. Early
diagnosis and radical resection, when possible, are
helpful in improving prognosis. However, it is usually* Correspondence: zhulinyang2013@163.com
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reproduction in any medium, provided the orimpossible to diagnose GBC at its early stages due to
the lack of obvious and specific symptoms. Common
symptoms do not develop until GBC is at an advanced
stage and include steady pain and discomfort in the
upper right abdomen. Clinically, over 90% of GBC
patients are diagnosed at an advanced stage when the
outcome of surgical therapy is very poor. Most patients
die within one year after diagnosis [2]. The majority of
GBC is adenocarcinoma (AC), accounting for about
90% of GBC, while the squamous cell carcinoma/. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 The CCT2 and PDIA3 expression and









male 19(41.3) 26(32.5) 0.986 0.352
female 27(58.7) 54(67.5)
Age (years)
≤ 45 3(6.5) 16(20.0) 4.143 0.042
> 45 43(93.5) 64(80.0)
Degree of differentiation





≤ 3 cm 20(43.5) 50(62.5) 4.280 0.039
> 3 cm 26(56.5) 30(37.5)
Gallbladder stones
no 18(39.1) 42(52.5) 2.093 0.148
yes 28(60.9) 38(47.5)
TNM stage




no 17(37.0) 30(37.5) 0.004 0.952
yes 29(63.0) 50(62.5)
Invasion
no 16(34.8) 31(38.8) 0.197 0.658
yes 30(62.5) 49(61.3)
Surgical
radical 14(30.4) 26(32.5) 0.215 0.898
palliative 18(39.1) 28(35.0)
biopsy 14(30.4) 26(32.5)
average survival time 10.07(4 to 25) 10.34(3 to 27) 0.014 0.906
CCT2
- 23(50.0) 31(46.2) 0.165 0.685
+ 23(50.0) 49(53.8)
PDIA3
- 20(43.5) 35(43.7) 0.001 0.976
+ 26(56.5) 45(56.3)
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and only account for 1.4% to 10.4% of GBC [1]. Because of
the low incidence of SC/ASC, their clinicopathological
features and biological behaviors have not been well
characterized. Most previous reports focus on patient
summaries or survival analyses [3-8]. To date, no molecular
biomarkers are available for SC/ASC to predict their
progression, metastasis, and prognosis.
CCT2 (chaperonin containing TCP1, subunit 2) is a
molecular chaperone, a subunit of the TCP1 complex,
which helps the correct folding of many proteins such
as actin and tubulin which are important in maintaining
the dynamic equilibrium of cell stability [9-15]. The
overexpression of CCT2 is highly related to the tumorigen-
esis, tumor progression, and prognosis of some cancers,
including hepatocellular carcinoma and colonic carcinoma
[16-18]. In addition, the expression of CCT2 is significantly
higher in gastric carcinoma than in normal gastric mucosa
[19]. Increased expression of CCT2 also contributes to
tumor cell resistance to chemotherapy and radiation
therapy [20].
PDIA3 (protein disulfide isomerase A3) is a member
of the disulfide isomerase family proteins [21,22] and is
a component of the molecular chaperone complex
containing calnexin and calreticulin, which promotes
the correct folding of newly synthesized glycoproteins in
the endoplasmic reticulum [21,22]. In the endoplasmic
reticulum, PDIA3 facilitates the formation of disulfide
bonds in glycoproteins through its redox isomerase activity.
The expression level of PDIA3 in cancer cells is linked to
tumor progression and prognosis of some human tumors.
For example, PDIA3 expression is increased in ovarian
cancer cells and has been considered as a potential
biomarker for ovarian cancer prognosis [23]. PDIA3
expression in hepatocellular carcinoma is positively
correlated with tumor grade and alpha-fetoprotein
(AFP) level [24]. Down-regulation of PDIA3 by siRNA
can inhibit the proliferation of breast cancer cells [25].
In addition, PDIA3 expression in cancer cells is critical
for tumor cell resistance to thermotherapy in A549
and UO31 cancer cell lines [26]. Therefore, the high
level of PDIA3 expression is an important potential
biomarker for rapid tumor progression and poor
prognosis.
Although their clinical importance was well studied
in other cancers, the expression of CCT2 and PDIA3
and their clinicopathological significance in gallblad-
der cancer have never been investigated. In this
study, we determined the expression levels of CCT2
and PDIA3 by immunohistochemistry staining in
tumor samples from 46 SC/ASC and 80 AC patients,
and then investigated the relationship between these
expression levels and tumor progression as well as
the prognosis.Methods
Patients
We collected data and tumor specimens from 46 patients
diagnosed with gallbladder SC/ASC (26 SC patients and 20
ASC patients) who were surgically treated in seven local
hospitals between January 1995 and December 2009. These
patients accounted for 4.34% (46/1,060) of all cases of
Figure 1 Expression of CCT2 and PDIA3 in gallbladder SC/ASC by IHC staining using EnVision system. (A) CCT2 positive expression in
poorly-differentiated gallbladder ASC. (B) CCT2 negative expression in well-differentiated gallbladder ASC. (C) PDIA3 positive expression in
poorly-differentiated gallbladder SC. (D) PDIA3 negative expression in moderately-differentiated gallbladder SC. Original magnification ×200.
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the same period. For comparison, we also collected tissue
samples from 80 patients with gallbladder AC from
these hospitals during the period from January 2000 to
December 2009. The study was approved by the Ethics
Committee of Human Study of Central South University.
Among the 80 AC patients, 26 patients were male and
54 patients were female, with a median age of 53.8 ± 9.9
(from 33 to 80) years. The pathological type (carcinoma
differentiation) included 27 cases with well-differentiated
carcinoma, 25 with moderately-differentiated carcinoma,
and 28 with poorly-differentiated carcinoma. Fifty
(62.5%) patients had tumors ≤ 3 cm in diameter, and 30
(37.5%) had tumors > 3 cm. Gallstones were identifiedFigure 2 Expression of CCT2 and PDIA3 in gallbladder AC by IHC using
gallbladder AC. (B) CCT2 negative expression in well-differentiated gallbladde
AC. (D) PDIA3 negative expression in well-differentiated gallbladder AC. Originas a companion factor in 38 patients (47.5%). Forty nine
patients (61.3%) had their tumor with adjacent tissue
invasion, and 50 patients (62.5%) had their tumor with
regional lymph node metastasis. Staging analysis revealed
that 8 cases were TNM stage I, 13 were stage II, 38 were
stage III, and 21 were stage IV. 26 patients (32.5%) under-
went radical resections, 28 patients (35.0%) underwent
palliative resections, and 26 patients (32.5%) underwent
biopsies without complete tumor removal.
Among the 80 AC patients, 26 patients were male and
54 patients were female, with a median age of 53.8±9.9
(from 33 to 80) years. The pathological type (carcinoma
differentiation) included 27 cases with well-differentiated
carcinoma, 25 with moderately-differentiated carcinoma,EnVision system. (A) CCT2 positive expression in poorly-differentiated
r AC. (C) PDIA3 positive expression in poorly-differentiated gallbladder
al magnification ×200.
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patients had tumors ≤3 cm in diameter, and 30 (37.5%)
had tumors >3 cm. Gallstones were identified as a com-
panion factor in 38 patients (47.5%). Forty nine patients
(61.3%) had their tumor with adjacent tissue invasion, and
50 patients (62.5%) had their tumor with regional lymph
node metastasis. Staging analysis revealed that 8 cases were
TNM stage I, 13 were stage II, 38 were stage III, and 21
were stage IV. 26 patients (32.5%) underwent radical
resections, 28 patients (35.0%) underwent palliative
resections, and 26 patients (32.5%) underwent biopsies
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Tumor maximum diameter (cm)
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aComparison between well-differentiated and moderately-differentiated SC/ ASC: PC
poorly-differentiated SC/ ASC: PCCT2 = 0.169; PPDIA3 = 0.057.The 46 patients with SC/ASC and 80 patients with
AC were followed for two years after surgery through
mail and phone calls. Among the 46 SC/ASC patients,
33 patients survived for < one year after surgery and
13 patients survived for ≥ one year, of whom only 4
survived for more than two years. Average survival
time for the SC/ASC patients was 10.07 ± 0.78
months. Of the 80 AC patients, 57 patients survived
for < one year after surgery and 23 patients survived
for ≥ one year, of whom only 9 survived for more than
two years. Average survival time for AC patients was
10.34 ± 0.63 months.and clinicopathological features of gallbladder SC/ASC
CCT2 PDIA3
) χ2 P Positive number (%) χ2 P
2.242 0.134 12(63.2) 0.580 0.446
14(51.9)
0.357 0.550 1(33.3) 0.702 0.402
25(58.1)
0.354 0.552 18(69.2) 3.930 0.047
8(40.0)
3.333 0.189 8(50.0) 5.940 0.051
12(50.0)
6(100.0)
5.121 0.020 9(45.0) 1.911 0.167
17(65.4)
0.365 0.546 12(66.7) 0.351 0.554
14(50.0)
5(41.7)
10.943 0.005 9(45.0) 7.013 0.028
12(85.7)
4.572 0.033 6(35.5) 4.945 0.026
20(69.0)
3.450 0.063 5(31.3) 6.376 0.012
21(70.0)
5.143 0.076 6(42.8) 6.987 0.030
8(44.4)
12(85.7)
CT2 = 0.333; PPDIA3 = 0.051; Comparison between moderately-differentiated and
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staining
Surgically obtained specimens were fixed with 4%
formaldehyde for 24 hours and then embedded in paraffin.
The paraffin-embedded tissues were sectioned at 4 μm
thickness for immunostaining with CCT2 and PDIA3
antibodies using peroxidase-based EnVision™ Detection
kit (Dako Laboratories, Carpinteria, CA, USA). Rabbit
anti-CCT2 and rabbit anti-PDIA3 antibodies were pur-
chased from Abgent Company (San Diego,, USA). The
percentage of positive cells (brown cytoplasmic and/or
nuclear staining) was calculated from 400 cells in 10
randomly selected fields. Cases with ≥ 25% positive cells









> 45 16 5(31.3)




Tumor maximum diameter (cm) 28 19(67.9)
≤ 3 cm
> 3 cm 50 22(44.0)
Gallbladder stones 30 21(70.0)
no
yes 42 19(45.2)














≤ 45 26 20(76.9)
aComparison between well-differentiated and poorly-differentiated adenocarcinoma
moderately-differentiated and poorly-differentiated adenocarcinoma: χ2 CCT2 = 0.79,cells were considered negative [27-29]. For a positive
control, a biopsy with positive expression of CCT2
and PDIA3 from Beijing Zhongshan Biotechnology
Company (Beijing, China) was used, and for a negative
control the primary antibody was replaced by 5% FBS
for the staining.
Statistical methods
Data were analyzed using the SPSS13.0 statistical package
from SPSS Inc (Chicago, USA).. The correlation between
the expression of CCT2 or PDIA3 with the histological or
clinical factors was analyzed using Chi square (χ2)
or Fisher’s exact test. Univariate survival analysis was
performed using the Kaplan-Meier method and log-rankand clinicopathological features of gallbladder AC
CT2 PDIA3
) χ2 P Positive number (%) χ2 P
0.000 0.990 14(53.8) 0.090 0.764
31(57.4)
4.073 0.044 7(43.8) 1.270 0.260
38(59.4)
5.326 0.070 12 (44.4) 11.840 0.000
10(40.0)
23(82.1)
5.099 0.024 23(46.0) 5.692 0.017
22(73.3)
2.577 0.108 25(59.5) 0.343 0.558
20(52.6)
7(33.3)
11.625 0.003 20(52.6) 12.092 0.002
18(85.7)
8.049 0.004 12(40.0) 5.150 0.020
33(66.0)
6.793 0.009 14(45.2) 2.529 0.112
31(63.3)
11.140 0.004 10(38.5) 7.940 0.019
15(53.6)
20(76.9)
: χ2 CCT2 = 5.24, P = 0.022; χ
2
PDIA3 = 8.44, P = 0.004; Comparison between
P = 0.374; χ2 PDIA3 = 9.98, P = 0.002.
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test were used for multivariate survival analysis and for
determining the 95% confidence intervals. P values < 0.05
were considered to be statistically significant.Table 4 Relationship between CCT2 and PDIA3
expression and clinicopathological characteristics and









male 19 10.74(6 to 24) 0.767 0.381
female 27 9.85(4 to 24)
Age (years)
≤45 3 15.67(8 to 24) 2.023 0.155
>45 43 9.84(4 to 24)
Pathological types
SC 26 10.19(4 to 24) 0.223 0.637
ASC 20 10.25(4 to 24)
Degree of differentiationa
well-differentiated 16 7.04(4 to 11)
moderately-Differentiated 24 8.92(4 to 18) 19.125 0.000
poorly-differentiated 6 5.83(4 to 9)
Tumor maximum diameter
(cm)
≤ 3 cm 20 14.35(7 to 24) 31.337 0.620
> 3 cm 26 7.04(4 to 11)
Gallbladder stones
no 18 8.22(4 to 12) 3.730 0.053
yes 28 11.50(4 to 24)
TNM stage
I + II 12 17.00(9 to 24)
III 20 9.20(7 to 15) 51.139 0.000
IV 14 5.86(4 to 8)
Lymph node metastasis
no 17 14.24(4 to 24) 16.219 0.000
yes 29 7.86(4 to 15)
Invasion
no 16 15.75(9 to 24) 32.271 0.000
yes 30 7.27(4 to 12)
Surgical
radical 16.64(10 to 24)
palliative 8.50(6 to 12) 50.165 0.000
biopsy 6.00(4 to 8)
CCT2
- 23 12.96(6 to 24) 14.073 0.000
+ 33 7.48(4 to 12)
PDIA3
- 20 12.75(6 to 24) 7.011 0.008
+ 26 8.27(4 to 24)Results
Clinicopathological features of SC/ASC and AC
As shown in Table 1, GBC was diagnosed more frequently
in older patients (> 45 years) than in those young patients
(≤ 45 years), and this was true for both SC/ASC (93.5%)
and AC (80%). However, tumors with poor differentiation
were more frequently identified in AC patients than in
SC/ASC patients (P < 0.05) (Table 1). On the other hand,
the percentage of patients with tumor mass > 3 cm was
higher in SC/ACS patients (56.5%) than in AC patients
(37.5) (P < 0.05). There were no significant differences in
gender, presence of gallstones, TNM stage, lymph node
metastases, adjacent tissue invasion, surgical procedure, orFigure 3 Correlation between positive expression of CCT2 or
PDIA3 and overall survival of patients with gallbladder SC/ASC.
A: Kaplan-Meier analysis of overall survival of gallbladder SC/ASC
patients according to the CCT2 expression in their cancers
(p < 0.001). B: Kaplan-Meier analysis of overall survival of gallbladder
SC/ASC patients according to PDIA3 expression in their cancers
(p = 0.008).
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AC (P > 0.05).
Expression of CCT2 and PDIA3 in SC/ASC and AC
The expression of CCT2 and PDIA3 by immunohisto-
chemical (IHC) staining was detected predominately in
the cytoplasm and occasionally in the nucleus (Figures 1
and 2). Among 46 SC/ASC tissue samples, 23 (50%)
samples showed CCT2 positive expression and 26
(56.5%) samples had PDIA3 positive expression (Table 1).
In the 80 AC specimens, we found that 43 (53.8%)
samples expressed CCT2 and 45 (56.3%) expressed
PDIA3 (Table 1). There were no differences in the expres-
sion patterns of CCT2 or PDIA3 between the different
GBC subtypes (P > 0.05).
Relationship between CCT2 and PDIA3 expression and
clinicopathological features of SC/ASC and AC subtypes
As shown in Table 2, the expression of CCT2 in tissue
samples of SC/ASC significantly correlated with tumor
size, TNM stage, and lymph node metastasis status. The
percentage of tumor samples with CCT2 expression
detected by IHC was significantly different between large
tumors and small tumors. 65.4% of large tumors (tumor
> 3 cm) had CCT2 expression whereas only 30% of
small tumors (tumor ≤ 3 cm) showed CCT2 expression.
Moreover, 85.7% of stage IV tumor samples expressed
CCT2, which was significantly higher than that of stage
III (40%) and stage I+II (20%) tumor samples. In
addition, CCT2 expression was detected more frequently
in tumors with lymph node metastasis (62.1%) than
those without lymph node metastasis (29.4%) (Table 2,
P = 0.03). There was no significant correlation between
CCT2 expression and patient gender, age, histopatho-
logical types, gallstones, adjacent tissue invasion, or
surgical procedure (P > 0.05).
In contrast to CCT2 expression, which showed no
significant differences between AC and ASC, PDIA3Table 5 Multivariate Cox regression analysis of survival rate i
Group Factors RC
Pathologic type SC/ASC .028
Degree of differentiation well-/moderately-/poorly-differentiated .856
Tumor diameter (cm) ≤ 3 cm/ > 3 cm 2.22
Gallbladder stones no/yes .669
TNM stage I + II / III / IV 1.23
Lymph node metastasis no/yes 1.64
Adjacent invasion no/yes 2.49
Surgical approach radical/palliative/biopsy 2.76
CCT2 −/+ 1.00
PDIA3 −/+ 0.88
RC regression coefficient, SE standard error, Wald Wald χ2, RR relative risk.was expressed more frequently in SC than ASC
(Table 2, P = 0.047). Moreover, a higher expression of
PDIA3 significantly correlated with higher TNM stage,
adjacent tissue invasion, and lymph node metastasis
(Table 2, P < 0.05).
Similar findings were observed in the AC subtype of
GBC. As shown in Table 3, the poorer the differentiation
of tumors, the higher the percentage of tumors with
CCT2 expression. In addition, the higher the TNM stage
of AC, the higher the percentage of tumors with CCT2
expression (Table 3, P < 0.05). Furthermore, we observed a
significant correlation between the expression of CCT2
and tumor size, invasion status, and lymph node metastasis
of AC as well as patient age (Table 3, P < 0.05).
In contrast to the expression of PDIA3 in SC/ASC, we
found that the expression of PDIA3 in AC significantly
correlated not only with large tumor size, higher TNM
stage, and lymph node metastasis, but also with poor
differentiation (Table 3, P < 0.05). However, no correlation
between PDIA3 expression and adjacent tissue invasion
was observed in AC analyzed (Table 3, P > 0.05).
Impact of CCT2 and PDIA3 expression on overall survival
of SC/ASC and AC patients
To further understand the importance of CCT2 and PDIA3
expression for SC/ASC and AC of GBC, we analyzed the
survival data of all 46 SC/ASC and 80 AC patients after
two years of following-up. Patients surviving longer than
two years were censored from the statistical analysis. We
chose two years as the mark point for our survival data
analysis because a majority of the patients died within two
years of surgery.
We found a significant correlation between CCT2 and
PDIA3 expression and the survival rate of SC/ASC
patients. The survival time of patients with CCT2 and
PDIA3 expression in their tumors was significantly
shorter than that of patients without CCT2 and PDIA3
expression in their tumors (P < 0.001 and P = 0.008 forn SC/ASC patients
SE Wald RR P 95% confidence interval
Lower limit Upper limit
.379 .005 1.028 .941 .489 2.162
.357 5.749 2.354 .016 1.169 4.738
5 .863 6.647 9.253 .010 1.705 50.223
.405 2.729 1.952 .099 .883 4.318
1 .457 7.256 3.425 .007 1.398 8.387
5 .578 8.100 5.181 .004 1.669 16.085
8 .796 9.848 12.158 .002 2.554 57.868
2 .822 11.290 15.831 .001 3.161 79.291
1 .547 3.349 2.721 .067 .931 7.950
9 .418 4.523 2.433 .033 1.072 5.519
Table 6 Relationship between CCT2 and PDIA3
expression and clinicopathological characteristics and









male 26 9.58(3 to 24) 2.567 0.109
female 54 11.30(3 to 24)
Age (years)
≤ 45 16 10.81(4 to 24) 0.003 0.956
> 45 64 10.72(3 to 24)
Degree of differentiationa
well-differentiated 27 15.07(5 to 24)
moderately-differentiated 25 10.60(4 to 24) 32.501 0.000
poorly-differentiated 28 6.68(3 to 14)
Tumor maximum
diameter (cm)
≤ 3 cm 50 13.70(6 to 24) 68.283 0.000
> 3 cm 30 5.80(3 to 10)
Gallbladder stones
no 42 10.19(3 to 24) 0.246 0.620
yes 38 11.34(4 to 24)
TNM stage
I+II 21 18.96(5 to 24)
III 38 9.29(6 to 15) 105.825 0.000
IV 21 5.14(3 to 7)
Lymph node metastasis
no 30 16.27(4 to 24) 42.372 0.000
yes 50 7.42(3 to 14)
Invasion
no 31 16.68(7 to 24) 55.535 0.000
yes 49 6.98(3 to 11)
Surgical
radical 26 18.31(10 to 24)
palliative 28 8.64(6 to 11) 113.141 0.000
biopsy 26 5.42(3 to 9)
CCT2
- 37 13.78(6 to 24) 17.876 0.000
+ 43 8.12(3 to 24)
PDIA3
- 35 13.46(5 to 24) 11.604 0.001
+ 45 8.62(3 to 24)
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In addition, Kaplan-Meier survival analysis of SC/ASC
patients revealed that the average survival time was highly
correlated with histological differentiation, tumor size,
TNM stage, lymph node metastasis, and adjacent tissue
invasion (Table 4, P < 0.005). Cox multivariate analysis
indicated that poor differentiation, tumor size > 3 cm,
TNM stage III or IV, lymph node metastases, adjacent
tissue invasion, no resection, and CCT2 and PDIA3
positive expression all negatively correlated with post-
surgery survival time, and positively correlated with
patient mortality rate (Table 5, P < 0.05). In addition,
CCT2 positivity was found to be an independent prognostic
risk factor for SC/ASC (Table 5, P = 0.033).
Similar to the findings in SC/ASC, we also found
that the expression of CCT2 and PDIA3 significantly
correlated with the shorter survival time of AC patients
(P < 0.001 and P = 0.001 for CCT2 and PDIA3, respectively,
in Table 6, and Figure 4). In addition, poor differentiation,
tumor size > 3 cm, TNM stage III or IV, lymph node
metastases, adjacent tissue invasion, no resection, and
positive expression of CCT2 and/or PDIA3 were all
negatively correlated with post-surgery survival rate,
and positively correlated with patient mortality rate
(Table 7, P < 0.05). In contrast to that in SC/ASC, both
CCT2 expression and PDIA3 expression were independent
prognostic risk factors for AC (Table 7, P = 0.04 and
P = 0.014 for CCT2 and PDIA3, respectively).
Discussion
In this study, we analyzed the expression of CCT2 and
PDIA3 by IHC staining in 46 SC/ASC samples as well as
in 80 AC samples, and found that both CCT2 expression
and PDIA3 expression were significantly correlated with
tumor progression and shorter survival time for patients
with SC/ASC and AC.
For the first time, we found that positive CCT2 expres-
sion in both SC/ASC and AC subtypes was significantly
associated with clinicopathological features, including
large tumor size, high TNM stage, and lymph node
metastasis. Moreover, positive expression of CCT2 in
AC also correlated with poor differentiation and adjacent
tissue invasion. These results, taken together, suggest an
important role for CCT2 in GBC progression. Given the
critical role of CCT2 in assisting the folding of actin,
tubulin, and other cytosolic proteins [14,15], we assumed
that the increased CCT2 expression in GBC cells might
be critical for these cells to meet the increased levels of
protein folding required during fast growth. In line with
this hypothesis, overall survival analysis showed that the
survival time of patients with positive CCT2 expression
was significantly shorter than that of patients with CCT2
negative expression. Moreover, CCT2 is identified as an
independent prognostic biomarker for both SC/ASC andAC patients in our multivariate survival analysis. In
addition to its up-regulation in GBC, CCT2 up-regulation
has been reported in other human tumors and is related
to drug-resistance of tumor cells [20]. Therefore, CCT2 in
GBC may also contribute to chemotherapeutic resistance,
which is important for the clinical treatment of GBC and
warrants further study.
Table 7 Multivariate Cox regression analysis of survival rate i
Group Factors RC
Degree of differentiation Well-/moderately-/poorly- differentiated 1.04
Tumor diameter (cm) ≤ 3 cm/> 3 cm 1.00
Gallbladder stones no/yes .07
TNM stage I + II / III / IV 1.22
Lymph node metastasis no/yes 1.18
Adjacent invasion no/yes 1.02
Surgical approach radical/palliative/biopsy 1.84
CCT2 −/+ .85
PDIA3 −/+ .68
RC regression coefficient, SE standard error, Wald Wald χ2, RR relative risk.
Figure 4 Correlation between CCT2 or PDIA3 expression and
overall survival of patients with gallbladder AC. (A) Kaplan-Meier
plots of overall survival of patients with gallbladder AC according to
CCT2 expression in their cancers (P < 0.001). (B) Kaplan-Meier
analysis of overall survival of patients with gallbladder AC according
to PDIA3 expression in their cancers (P = 0.001).
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stress response [30]. PDIA3 is also connected to the apop-
totic process and has an anti-apoptotic effect in the melan-
oma cells after induction of endoplasmatic reticulum stress
[31]. Overexpression of PDIA3 has been reported in various
tumors, including melanomas, cervical carcinoma, ovarian
carcinoma, esophageal squamous cell carcinoma, and
hepatocellular carcinoma, and is associated with tumor
progression, metastasis and poor patient survival rate
[22-24,32-35]. Consistent with these studies, we found
that positive PDIA3 expression was significantly associated
with higher TNM stage, surrounding tissue invasion and
lymph node metastasis in both SC/ASC and AC subtypes
of GBC. In addition, PDIA3 expression was correlated
with poor differentiation and large tumor size in the AC
subtype. Furthermore, positive PDIA3 expression was
significantly related to the overall survival of patients with
both SC/ASC and AC. Therefore, the expression level of
PDIA3 in AC and SC/ASC reflected the progression and
clinical behavior of gallbladder cancer and might be an
important biomarker of poor prognosis. It should be noted
that in some cancer types, down-regulation of PDIA3 is
related to tumor progression. For example, a lack of
PDIA3 expression has been correlated with increased
tumor invasion and the advanced stage of gastric cancer,
and has therefore been proposed as a good prognostic
marker [36]. In addition, PDIA3 expression is down-
regulated in metastatic prostate cancer, suggesting that
down regulation of PDIA3 might play a role in the late
onset of prostate cancer progression [37]. Therefore, the
expression of PDIA3 and its role in tumor progression
seems to be tumor type specific.
Although there are differences in histopathological
features and incidence between SC/ASC and AC subtypes
of GBC, our study provided evidence that both SC/ASC
and AC have common molecular features, that is, positive
expression of CCT2 and PDIA3, and that the expression
of CCT2 and PDIA3 in tumor cells correlates with tumor
progression and poor prognosis.n AC patients
SE Wald RR P 95% confidence interval
Lower limit Upper limit
0 .497 4.379 2.829 .036 1.068 7.494
3 .410 5.985 2.726 .014 1.221 6.090
7 .246 .098 1.080 .754 .667 1.749
7 .419 8.576 3.411 .003 1.500 7.754
3 .454 6.790 3.264 .009 1.341 7.947
1 .507 4.055 2.776 .044 1.028 7.499
9 .424 19.017 6.353 .000 2.768 14.586
3 .296 8.305 2.347 .004 1.314 4.192
2 .278 6.018 1.978 .014 1.147 3.411
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In conclusion, positive expression of CCT2 and PDIA3
are associated with large tumor size, high TMN stage,
lymph node metastasis, adjacent tissue invasion, and poor
prognosis of SC/ASC and AC. Expression of CCT2 and
PDIA3 may reflect the progression and clinical behavior
of GBC. CCT2 and PDIA3 could be important diagnostic
and prognostic biomarkers for both the SC/ASC and AC
subtypes of GBC.
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